Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: memantine Clear all
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 2:09 AM EDT
Terminated Phase 1 Interventional

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

NCT01430351
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

NCT01972074
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 3 Interventional

Clinical Trial of Memantine for Major Depression

NCT00040261
View directory record Official record
Conditions
Depression
Interventions
Memantine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 2:09 AM EDT
Completed No phase listed Observational

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Memantine XR-pregabalin combination therapy
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Early Phase 1 Interventional

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT04217694
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Primary Central Nervous System Neoplasm
Interventions
Cogstate Assessment Battery, Memantine, Memantine Hydrochloride
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease

NCT03703856
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 83 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 2:09 AM EDT
Recruiting Phase 2 Interventional

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Memantine Hydrochloride, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

NCT04033419
View directory record Official record
Conditions
Cognitive Decline, Chemo-brain
Interventions
Memantine
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 2, 2026, 2:09 AM EDT
Not listed Phase 4 Interventional

Memantine for Post-Operative Pain Control

NCT01041313
View directory record Official record
Conditions
Pain, Post-operative
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

NCT01585168
View directory record Official record
Conditions
Healthy
Interventions
Memantine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCT03860597
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
Interventions
Memantine, Placebos
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2

NCT00134901
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Memantine, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 2, 2026, 2:09 AM EDT
Withdrawn Phase 1 Interventional

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AGN-242071, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Allergan
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT03527472
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Memantine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

NCT00300716
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Memantine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 2, 2026, 2:09 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)

NCT01372449
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
Evdokia Anagnostou
Individual
Eligibility
6 Years to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Results available

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

NCT00120874
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Individualized management of AD including caregiver training, Memantine
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Sep 2, 2026, 2:09 AM EDT
Not yet recruiting Phase 1 Interventional

Escalating Doses of Memantine in Down Syndrome (MEDS-123)

NCT07531940
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 2:09 AM EDT
Completed No phase listed Observational

Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome

NCT02854917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 2, 2026, 2:09 AM EDT
Completed Not applicable Interventional Results available

Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus

NCT00928954
View directory record Official record
Conditions
Nystagmus
Interventions
gabapentin, memantine
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Sep 2, 2026, 2:09 AM EDT